In conclusion, with the use of mathematical model analyses, we have shown that DI/cle cannot fully account for interindividual variation in blood glucose levels among individuals with type 2 diabetes who are treated with an SGLT2 inhibitor, whereas PI/cle is able to do so, at least in part. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.